medigraphic.com
ISSN 1561-2929 (Print)

2015, Number 2

<< Back Next >>

RCAN 2015; 25 (2)

Homocysteine as indicator of the effectiveness of percutaneous coronary interventionism

Rosabal NEL, Denis AR, Leyva QAY

Language: Spanish
References: 49
Page: 276-291
PDF size: 349.07 Kb.


ABSTRACT

Rationale: Homocystein (Hcy) is a sulfurcontaining aminoacid appearing as an intermediate product of the metabolism of methionine. Increased Hcy serum values might indicate augmented cardiovascular risk. There are controversies surrounding the role of Hcy as indicator of the effectiveness of percutaneous coronary interventionism (PCI). Objective: To assess the association between serum Hcy and the effectiveness of PCI. Study design: Observational, prospective, analytical study. Material and method: Hcy serum values were obtained from 121 patients (Males: 67.8%; Ages ≥ 60 years: 51.2%) complaining from coronary disease in whom a PCI was completed between October 2013 and May 2015 at the “Hermanos Ameijeiras” Clinical surgical Hospital (La Habana, Cuba). Major adverse cardiac events (MACE) were recorded after completion of PCI: death, non-fatal acute myocardial infarction, and indication of a new revascularization of the target lesion. Results: Average Hcy serum values were 12.3 ± 3.8 µmol.L-1. Twenty-three point one percent of studied subjects presented with Hcy values › 15 µmol.L-1. Twenty four point eight percent of intervened patients developed a MACE. Elevated Hcy serum values were not associated with MACE after 12 months follow-up (p = 0.66). Hcy was not useful as prognostic indicator of major adverse coronary events in subjects with coronary disease in whom a PCI was completed.


REFERENCES

  1. Macin SM, Bono J, Ramos H, Rengel E, Suasnabar R, Zapata G; et al. Guías de manejo de cardiopatía isquémica crónica: Angina crónica estable. Rev Fed Arg Cardiol 2009;38(Supl 1):S1-S23.

  2. Dirección Nacional de Estadísticas y Registros Médicos. Anuario Estadístico de Salud 2012. MINSAP Ministerio de Salud Pública. La Habana: 2013.

  3. Netteship JE, Jones RD, Channer KS, Jones TH. Testosterone and coronary artery disease. En: Advances in the management of testosterone deficiency (Editor: Jones TH). Karger. Basel: 2009. pp 91-107.

  4. Wingard DL, Suarez L, Barrett-Connor E. The sex differential in mortality from all causes and ischaemic heart disease. Am J Epidemiol. 1983;117:165-72.

  5. Sánchez Cuevas M, Jiménez Reséndiz SP, Morgado Vázquez JS. La homocisteína: Un aminoácido neurotóxico. REB 2009;28:3-8.

  6. Lanyau Domínguez Y, Macías Matos C. Deficiencia de vitaminas y enfermedad de Alzheimer. Rev Cubana Salud Pública 2005;31(4):0-0. Disponible en: http://www.imbiomed.com.mx/1/1/articu los.php?method=showDetail&id_articulo =34406&id_seccion=1508&id_ejemplar =3540&id_revista=79. Fecha de última visita: 13 de Marzo del 2015.

  7. Nevado Jr JB, Imasa MS. Homocysteine predicts adverse clinical outcomes in unstable angina and non-ST elevation myocardial infarction: Implications from the folate intervention in non-ST elevation myocardial infarction and unstable angina study. Coron Artery Dis 2008;19:153-61.

  8. Chichizola C, Ludueña B, Mastandrea C, Sánchez H. El valor diagnóstico de la homocisteína. Utilidad clínica. Rev Arg Endocrinol Metab 2003;40:32-42.

  9. Blanco Vaca F. Hiperhomocisteinemia asociada a múltiples enfermedades, desde la aterotrombosis al Alzheimer: ¿Casualidad o causalidad? Clin Invest Arterioscl 2003;15:69-72.

  10. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002;288:2015-22.

  11. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002;325:1202.

  12. Park SH, Kim H, Lee KJ. Correlations between homocysteine and grey matter volume in patients with Alzheimer's disease. Psychogeriatrics 2015. PubMed PMID: 25560091.

  13. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M; et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: Sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 1994;40:873-81.

  14. Lupattelli G, Rufini S, Locati EH, Lombardini R, Ciuffetti G, Siepi D; et al. Hyperhomocyst(e)inemia is associated with carotid atherosclerosis. Angiology 1999;50:823-30.

  15. Malinow MR. Homocysteine and arterial occlusive diseases. J Intern Med 2014;236:603-17.

  16. Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 1992;200:218-29.

  17. TePoele-Pothoff MT, van den Berg M, Franken DG, Boers GH, Jakobs C, de Kroon IF; et al. Three different methods for determination of total homocysteine in plasma. Ann Clin Biochem. 1995;32: 218-20.

  18. Andersson A, Isaksson A, Brattstršm L, Hultberg B. Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolumn derivatization. Clin Chem 1993;39: 1590-7.

  19. Ford AH, Flicker L, Hankey GJ, Norman P, van Bockxmeer FM, Almeida OP. Homocysteine, methyl-ene-tetra-hydrofolate reductase C677T polymorphism and cognitive impairment: The Health in Men Study. Mol Psychiatry 2012;17: 559-66.

  20. Balta I, Balta S, Ozturk C, Demirkol S. Plasma homocysteine level in patients with Behçet's disease. Int J Rheum Dis 2015;18:582. PubMed PMID: 2554610.

  21. Muñoz JL, Ellis SG Cannon CP, Battler A, Brindis RG, Cox, Every NR; et al. American College of Cardiology key data elements and definition for measuring the clinical management and outcomes of patients with acute coronary syndromes. J Am Coll Cardiol 2001; 38:2114-30.

  22. Chua S, Wu CJ, Chang HW, Hang CL, Chen CJ, Yang CH, Yip HK. Impact of elevated plasma total homocysteine concentration on coronary atherosclerosis in Chinese patients with acute myocardial infarction undergoing primary coronary intervention. Int Heart J 2005;46:181-93.

  23. Orduñez García PO, Cooper R, Espinosa Brito AD, Iraola Ferrer AD, Bernal Muñoz JL, Rosa Linares Y. Enfermedades cardiovasculares en Cuba: Determinantes para una epidemia y desafíos para la prevención y control. Rev Cubana Salud Pública 2005;31(4):0-0. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_ issuetoc&pid=0864- 346620050004&lng=es&nrm=iso. Fecha de última visita: 15 de Mayo del 2014.

  24. Meriño Ibarra E, Hierro García D, Herrera González A, Nasiff Hadad A. Utilidad de la asociación entre factores de riesgo cardiovasculares y la aterosclerosis carotídea en el diagnóstico de cardiopatía isquémica. Rev Cubana Med 2005;44(3-4):1-7.

  25. Acelajado MC, Calhoun DA. Resistant hypertension, secondary hypertension, and hypertensive crises: Diagnostic evaluation and treatment. Cardiol Clin 2010;28:639-54.

  26. Sahakya K, Klein BEK, Myers CE, Tsai MY, Klein R. Novel risk factors in longterm hypertension incidence in type 1 diabetes mellitus. Am Heart J 2010;159:0-0. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/article s/PMC2891971/. Fecha de última visita: 15 de Mayo del 2014.

  27. Byrne R, Lijima R, Mehilli J, Pache J, Schulz S, Schömig A; et al. Tratamiento de la reestenosis de stents liberadores de paclitaxel mediante implantación de stents liberadores de sirolimus. Resultados angiográficos y clínicos. Rev Esp Cardiol 2008;61:1134-9.

  28. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: Description of a new technique and preliminary report of its applicattions. Circulation 1964;30:654.

  29. Cooney MT, Cooney HC, Dudina A, Graham IM. Total cardiovascular disease risk assessment: A review. Curr Opin Cardiol 2011;26:429-37.

  30. Álvarez González L. Variables asociadas a reestenosis clínica en pacientes con intervencionismo coronario percutáneo con stent convencional. Tesis de terminación de Residencia en Cardiología. Hospital Clínico Quirúrgico “Hermanos Ameijeiras”. La Habana: 2009.

  31. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: Methods and clinical applications. Clin Chem 1993;39:1764-79.

  32. Santana Porbén S, Martínez Canalejo H. Manual de Procedimientos Bioestadísticos. Segunda Edición. EAE Editorial Académica Española. ISBN-13: 9783659059629. ISBN-10: 3659059625. Madrid: 2012.

  33. Ghassibe-Sabbagh M, Platt DE, Youhanna S, Abcheec AB, Stewartd K, Badro DA. Genetic and environmental influences on total plasma homocysteine and its role in coronary artery disease risk. Atherosclerosis 2012;222:180-6.

  34. Wang CY, Chen ZW, Zhang T, Liu J, Chen SH; et al. Elevated plasma homocysteine level is associated with ischemic stroke in Chinese hypertensive patients. Eur J Intern Med 2014;25: 538-44.

  35. van Dijk SC, Smulders YM, Enneman AW, Swart KM, van Wijngaarden JP; et al. Homocysteine level is associated with aortic stiffness in elderly: Cross-sectional results from the B-PROOF Study. J Hypertens 2013;31:952-9.

  36. Zhou S, Zhang Z, Xu G. Notable epigenetic role of hyperhomocysteinemia in atherogenesis Lipids Health Dis 2014;13:0-0. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/article s/PMC4156629/. Fecha de última visita: 15 de Abril del 2015.

  37. Brustolin S, Giugliani R, Félix T. Genetics of homocysteine metabolism and associated disorders. Braz J Med Biol Res 2010, 43:1-7.

  38. Quesada Araya A, Bolaños Cubillo A. Hiperhomocisteinemia y enfermedad arterial coronaria. Revista Médica Costa Rica Centroamérica 2012;69(600):83-90.

  39. De Koning L, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003;36: 431-41.

  40. Karolczak K, Olas B. Mechanism of action of homocysteine and its thiolactone in hemostasis system. Physiol Res 2009;58:623-33.

  41. Masoomi M, Bahrampour A, Mireskandri M, Nematolahi A. Plasma homocysteine concentrations in young patients with acute myocardial infarction. ARYA Atherosclerosis Journal 2007;2(4):193-6.

  42. Leyva Quert AY, León Gurkin1 M, Valdés Recarey MA, Ponte Gonzalez G, Mendoza Ortíz JL. Rodríguez Blanco S. Factores asociados a la recurrencia de la re-estenosis intra-stent coronario convencional. Rev Cubana Cardiol Cir Cardiovasc 2015;21(1):0-0. Disponible en: http://www.revcardiologia.sld.cu/index.p hp/revcardiologia/article/viewFile/564/6 96. Fecha de última visita: 22 de Mayo del 2015.

  43. Suárez García I., Gómez Cerezo JF, Ríos Blanco JJ, Barbado Hernández F, Vázquez Rodríguez JJ. La homocisteína. ¿El factor de riesgo cardiovascular del próximo milenio? Anales Medicina Interna 2001;18(8)211-7.

  44. García Pinilla JM, de Teresa Galván E. Homocisteína y cardiopatía isquémica: ¿Marcador pronóstico o diana terapéutica? Cardiocore 2011;46:36-8.

  45. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, Loop FD. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/ American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Subcommittee on Percutaneous Transluminal Coronary Angioplasty. Circulation 1988;78:486-502.

  46. Juhola J, Magnussen CG, Viikari JS, Kähönen M, Hutri-Kähönen N, Jula A; et al. Tracking of serum lipid levels, blood pressure, and Body Mass Index from childhood to adulthood: The Cardiovascular Risk in Young Finns Study. J Pediatr 2011;21:1-7.

  47. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH; et al. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation 2011; 123:2292-333.

  48. Guallar Castillón P, Gil Montero M, León Muñoz LM, Graciani A, Bayán Bravo A, Taboada J; et al. Magnitud y manejo de la hipercolesterolemia en la población adulta de España, 2008-2010. El Estudio ENRICA. Rev Española Cardiol 2012;65(6):0-0. Disponible en: http://www.revespcardiol.org/es/magnitu d-manejo-hipercolesterolemia-poblacionadulta/ articulo/90136628/. Fecha de última visita: 15 de Abril del 2015.

  49. de la Noval García R, Armas Rojas NB, de la Noval González I, Fernández González Y, Pupo Rodríguez HB, Dueñas Herrera A, Nordet Cardona P. Estimación del Riesgo Cardiovascular Global en una población del Área de Salud Mártires del Corynthia. La Habana, Cuba. Rev Cubana Cardiol Cir Cardiovasc 2011;17(1):62-68




2020     |     www.medigraphic.com